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translation of extracellular vesicles for 
therapeutic and diagnostic applications
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There is growing interest in the potential and use of extracellular vesi-
cles (EVs) for a range of diagnostic and therapeutic applications. EVs have 
been shown, in some instances, to mediate the regenerative effects elic-
ited by stem cell therapies. As such, they are being studied to identify the 
extent to which these extracellular bodies can be employed as a thera-
peutic entity, and significant R&D activity is underway to further under-
stand their clinical and commercial potential. However, successful trans-
lation will first require further characterization and standardization of EV 
production, as well as addressing some of the major challenges associated 
with their reproducible manufacture. This includes the capacity to pro-
duce EVs at a scale that is both clinically and commercially effective. This 
article will highlight some of the bioprocessing and manufacturing con-
siderations and challenges associated with the standardized production 
of EVs.    
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OVERCOMING DOWNSTREAM  
BOTTLENECKS IN CELL & GENE  
THERAPY MANUFACTURING
The next generation of therapeu-
tics will employ the use of whole 
cells, such as human stem cells 
or gene-modified cells, for the 
treatment of acute and chronic 
conditions. This has resulted in 
significant research and develop-
ment activity to establish large-scale 
production platforms for human 
stem cells, both pluripotent (e.g., 
embryonic and induced pluripo-
tent) and multipotent (mesenchy-
mal and hematopoietic). Whilst 
there have been numerous clinical 
trials involving the use of human 
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mesenchymal stem/stromal cells 
(MSCs) and general recognition 
that the cells are safe to administer 
and elicit a therapeutic response, 
it is unclear as to the underlying 
mechanism by which the cells in-
duce a therapeutic effect. Evidence 
suggests that rather than engrafting 
and integrating with the host tissue 
as originally expected, these mul-
tipotent cells primarily exert their 
therapeutic effects via the secretion 
of trophic factors and extracellular 
vesicles (EVs) into the surrounding 
environment [1,2]. As such, there 
has been growing interest in the role 
of EVs, with these secreted extracel-
lular bodies potentially representing 
the active pharmaceutical agent for 
MSCs. Studies have been conduct-
ed demonstrating the therapeutic 
potential of EVs across a wide range 
of different clinical applications 
including inflammation, cardiovas-
cular diseases, wound healing and 
hypertension [3–5]. In view of this 
potential, efforts are now being un-
dertaken to explore the standardiza-
tion and manufacturability of EVs 
at a scale that is both clinically and 
commercially relevant.
THE ROLE OF  
EXTRACELLULAR VESICLES 
Amongst the complex mixture of 
factors comprizing the MSC secre-
tome, vesicles are considered par-
ticularly significant since they have 
been shown to mediate endocrine 
and paracrine signaling in a num-
ber of tissues [6]. Vesicles can be dif-
ferentiated by their size, molecular 
content and mechanism of biogene-
sis. Within the majority of biofluids 
studied thus far, there exists a het-
erogeneous mixture of vesicles that 
range in size from 30 to 2000 nm 
(Figure 1). They fall into three main 
categories, which include: apoptot-
ic bodies; shedding- or micro-vesi-
cles; and exosomes (Figure 1). From 
a therapeutic perspective, shedding 
vesicles and exosomes have received 
considerable attention and we shall 
henceforth refer to them collec-
tively as EVs. As a consequence of 
their biogenesis, the lumen of each 
vesicle is loaded with a complex 
mixture of proteins and nucleic ac-
ids derived from the plasma mem-
brane and cytoplasm. As such, the 
biological profiles of EVs mirror 
the parental cells from which they 
originated and much attention has 
been directed toward deciphering 
the molecular signature of EVs and 
using this information to identify 
biomarkers for the prediction of a 
variety of diseases (eg: cancers) [7]. 
However, it is becoming apparent 
that there is also an opportunity 
to exploit the natural communi-
cative roles of these nano-particles 
for regenerative applications. To 
date, EVs have been implicated in 
a number of physiological processes 
that have long been of interest to 
the tissue engineering communi-
ty and include angiogenesis, ossi-
fication, matrix remodeling and 
immunity [8]. As such, the consid-
erable value of EVs as an acellular 
source of valuable biological factors 
that may be combined with scaf-
folds, or indeed used in isolation, 
to bring about a therapeutic benefit 
is becoming increasingly evident. 
There are considerable advantag-
es in a shift towards an EV-based 
approach to regenerative medicine 
when compared with current cell-
based approaches. Perhaps the most 
appealing prospect is that EVs can 
be fully characterized before admin-
istration with no risk of transforma-
tion or immunogenicity (at least for 
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stem cell-derived exosomes). The 
lack of immunogenicity is signif-
icant, as it means that like MSCs, 
the EV source does not strictly have 
to be autologous. The presence of a 
bilipid membrane that confers add-
ed stability within the circulation, 
combined with a natural homing 
capacity can be exploited to stably 
deliver therapeutic molecules to 
damaged or diseased sites with-
in the body. The cell-derived lipid 
membrane also allows for simple 
and effective loading of EVs with 
molecules such as RNAs to enhance 
their therapeutic efficacy, while 
their protein component limits rap-
id clearance from the circulation 
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Biogenesis and release of microvesicles and exosomes.
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Microvesicles 
Microvesicles bud directly from the cell membrane and incorporate local cytosolic proteins and nucleic acids, as well as proteins found 
within the parent cell membrane. Exosomes are generated through an endocytic pathway, whereby intraluminal budding results in 
the formation of early endocytic vesicles that contain a heterogeneous mixture of factors. Exosomes begin to form within the early 
endosome and mature within the late endosome or multivesicular body (MVB). Contents of the endosome can also be targeted for 
lysosomal degradation. Exosomes enter the extracellular environment when the late endosome fuses with the cell membrane. 
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[9]. The natural physiological role 
of these small particles in cell–cell 
communication, both local and dis-
tant, means that they are naturally 
tailored for drug delivery, and as 
such lend themselves to the delivery 
of a variety of molecular factors to 
promote tissue regeneration. If the 
mode of action (MoA) is established 
and EVs can be reproducibly man-
ufactured at scale, they have the po-
tential to make a significant impact 
as a biologic. 
CLINICAL & COMMERCIAL 
APPLICATIONS OF EVS
To date, several clinical trials have 
sought to evaluate the efficacy of 
EV-based therapies. The majority 
of trials have applied EVs as an-
ti-cancer agents, where EVs isolated 
from patients were pre-activated or 
administered in combination with 
anti-tumor peptide antigens raised 
against the cancer cells and then 
reintroduced to patients to initiate 
an immune response that specif-
ically targeted the tumor. Such an 
approach has been applied to target 
metastatic melanoma [10], colorec-
tal cancer [11] and non-small-cell 
lung cancer [12]. These trials have 
shown initial promise with pro-
longed tolerance to EV administra-
tion reported and only mild inflam-
matory responses documented as a 
side effect.
From a regenerative perspective, 
the number of EV-based clinical 
studies is steadily increasing as a 
greater understanding of the role EVs 
play in a regenerative context is de-
veloped. The significant regenerative 
effects of MSC-derived exosomes 
first came to the attention of the 
scientific community in 2010 when 
they were successfully applied in a 
murine model of myocardial isch-
emia/reperfusion injury, promoting 
neoangiogenesis with a subsequent 
reduction in the area of infarct-relat-
ed damage [13]. Subsequent studies 
have confirmed that the positive ef-
fects of stem cell therapies following 
ischemia are largely a result of vesi-
cles that orchestrate regeneration 
through the delivery of a biological 
cargo, such as micro-RNAs that in-
clude miR-146a [14]. 
Most recently, a Phase 1 clinical 
trial has been established to inves-
tigate the effects of EV-rich plasma 
for enhanced cutaneous wound 
healing (NCT02565264). Plate-
let-rich plasma (PRP) has long been 
observed to provide significant ther-
apeutic benefits for a multitude of 
ailments including chronic tendon 
injury, fractures and sports-related 
muscle injury. However, due to do-
nor-variation and a lack of under-
standing of the specific MoA, PRP 
is difficult to standardize. Exosomes 
derived from PRP have previously 
been shown to deliver many of the 
principal growth factors thought to 
be, in part, responsible for it’s ther-
apeutic effects [15]. To the authors’ 
knowledge, this represents the only 
active clinical trial applying EVs 
for the purpose of tissue healing/
regeneration.
In addition to the aforemen-
tioned clinical trials, EVs have been 
applied with successful outcomes 
in animal models of acute kidney 
toxicity [16]; neurological disorders 
such as multiple sclerosis [17] and 
sciatic nerve injury [18]; and gastro-
intestinal diseases such as induced 
colitis [19] and drug-induced in-
flammatory bowel disease [20]. De-
spite the relatively recent emergence 
of EVs as a potential therapeutic 
intervention, there are now mul-
tiple companies established with a 
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focus on commercializing EVs for 
clinical and/or diagnostic use (Ta-
ble 1). These include EVs from a 
range of different cell sources and 
for the treatment of a range of dif-
ferent clinical indications. 
Other technologies and ap-
proaches inspired by exosomes in-
clude exosome-mimetic nanovesi-
cles, which have demonstrated the 
ability to deliver chemotherapeu-
tics to the tumor tissue after sys-
temic administration [21]. Through 
the use of a serial extrusion meth-
od with multiple filters of reducing 
pore size, monocytes and macro-
phages were broken down to pro-
duce the nanovesicles. The authors 
suggest that such nanovesicles share 
similar properties with exosomes 
but have a 100-fold higher produc-
tion yield [21]. This approach of 
using cell membrane-derived par-
ticles for targeted therapeutic de-
livery has been an increasing area 
of research focus [22]. Gao and col-
leagues developed a system to make 
cell membrane nanovesicles, which 
employed nitrogen cavitation 
to disrupt activated neutrophils 
[23]. The authors demonstrated 
the nanovesicles could selective-
ly bind inflamed vasculature and 
that the administration of the 
vesicle with TPCA-1 resulted in 
the significant reduction of acute 
lung inflammation in mice [23]. 
More recently, the authors have 
suggested that there is a 16-fold 
increase in the production of EVs 
via nitrogen cavitation compared 
to naturally secreted EVs and are 
easier to scale-up than tradition-
al EV production methods [24]. 
 
 
 
BIOPROCESSING & MANU-
FACTURE OF EVS 
Whilst the clinical utility of EVs in 
a regenerative context is becoming 
more apparent, there are numerous 
challenges to be addressed before 
EVs can represent a real clinical 
alternative. These include repro-
ducibility and isolation, storage, 
scalability (methods for mass pro-
duction required to achieve clinical 
scale), characterization, safety and 
regulation. 
  f TABLE 1
Companies involved in EV R&D for therapeutic or diag-
nostic applications.
Company Cell source
Capricor Therapeutics Cardiosphere-derived cell
Codiak Biosciences Mesenchymal stem cells
Creative Medical Technologies 
Holdings inc.
Amniotic fluid-derived stem 
cells
Evox Therapeutics Dendritic cells
Exogenus Therapeutics Umbilical cord blood
Exosome Diagnostics Serum/plasma and urine 
samples
Exosome Sciences Plasma samples
Exosomics Siena SpA Prostate and colorectal cancer 
cells
Kimera Labs Amniotic fluid-derived stem 
cells
ReNeuron CTX neural stem cell
RoosterBio Mesenchymal stem cells
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Reproducibility & isolation
Reproducibility is dependent on 
several factors that begin at the 
donor and cellular level. Since the 
properties of EVs is dependent on 
the cells from which they originate 
and the conditions in which these 
cells are maintained, it is of critical 
importance that these variables are 
standardized to provide a reproduc-
ible population of EVs that elicit 
an optimal therapeutic effect. Do-
nor-to-donor variation is likely to 
impact on the clinical efficacy of a 
particular EV therapy. In order to 
reduce the risk of variation it is im-
portant that the MoA of each EV 
therapy is understood so that it can 
be standardized and its therapeutic 
effects reproducible. 
Perhaps one of the most pertinent 
questions within the field is how 
these valuable biological particles 
can be isolated at scale in a way that 
retains functionality and minimizes 
the inclusion of non-vesicular con-
taminants, such as membrane frag-
ments and extracellular proteins. 
EVs are most typically characterized 
based on their size and protein/lipid 
content. Current isolation methods 
have varying influence on the recov-
ery of EV protein and RNA yield 
and modern solutions will likely be 
required to generate clinical grade 
EVs [25,26]. Many recent examples 
have been published describing the 
merits and disadvantages of several 
distinct methods for the isolation 
of EVs from a diverse range of sam-
ples, which includes culture medi-
um, urine, plasma and other body 
fluids [27]. 
Of the multitude of isolation 
methods reported in the literature, 
differential ultracentrifugation re-
mains the oldest and most widely 
applied method. This technique 
selectively sediments components 
of interest based on their size and 
density. However, ultracentrifuga-
tion often results in a high degree 
of variation [28]. Furthermore, it is 
a lengthy process that provides rel-
atively low yields of between 5 and 
25% of the initial starting yield [29]. 
One way to increase the purity of 
vesicle fractions is through sucrose 
gradient centrifugation, which sep-
arates vesicles based on their vary-
ing flotation densities. The smallest 
vesicles (exosomes) are recorded to 
have flotation densities of 1.08–
1.22g/mL on sucrose, Optiprep or 
iodixanol gradients [30]. The advan-
tage of such methods is that they are 
less prone to capture contaminating 
cell debris. The downside is that 
these methods are labor intensive 
and not suited for high-throughput 
applications.
More rapid methods include 
size-exclusion chromatography 
(SEC) or EV precipitation. Pre-
cipitation exploits the differential 
solubility of EVs in different sol-
vents, such as poly-ethylene glycol 
(PEG) or PRotein Organic Solvent 
PRecipitation (PROSPR). A range 
of commercial isolation kits have 
recently become available that are 
designed to sediment exosomes at 
lower speeds by precipitation with 
PEG or similar substances. These 
include the Total Exosome Isolation 
Kit (LifeTechnologies, USA) and 
ExoSpin Exosome Purification Kit 
(Cell Guidance Systems, USA). As 
such, this method is advantageous 
in some respects because it does not 
require specialist equipment, min-
imizes the risk of damage induced 
by high centrifugal force and re-
duces labor. However, it is compar-
atively expensive when compared 
with ultracentrifugation and may 
allow the precipitation of non-exo-
somal debris that will interfere 
EXPERT INSIGHT 
689Cell & Gene Therapy Insights - ISSN: 2059-7800 
with the detection of EV markers 
[31]. This will likely hinder efforts 
to standardize EV-based therapies 
[32]. SEC appears to be a promis-
ing method that is reported to en-
able the isolation of a highly pure 
population of EVs within a defined 
size-range, while not significantly 
impacting the downstream analy-
sis of EV surface marker proteins. 
This method has been employed 
by Böing and colleagues who were 
able to isolate EVs with a diameter 
of >70 nm from platelet-free su-
pernatant of platelet concentrates 
without co-isolation of protein 
aggregates [33]. The group success-
fully demonstrated the technique’s 
potential as a single-step unit op-
eration for efficient EV isolation. 
Moreover, SEC is an established 
downstream processing technique 
for the purification of intracellular 
proteins in the biopharmaceutical 
industry, making it an established 
and attractive isolation method for 
EVs. However, the technique has 
only recently been considered for 
the EV isolation and additional in-
vestigations are required to under-
stand the unit operations efficiency 
at larger scales.
Other techniques that have been 
used in the biopharmaceutical in-
dustry for the purification of bio-
logics have also been considered for 
the isolation of EVs; this includes 
tangential flow filtration (TFF), 
which has been used for isolation 
and concentration of EVs in con-
junction with other process steps. 
Indeed, TFF has been used in con-
junction with ultracentrifugation 
for isolation of therapeutic EVs in 
clinical trials [10,12]. Whilst filtra-
tion (both ultra- and nano-filtra-
tion) are established techniques and 
used widely in biopharmaceutical 
production with proven scalability, 
current processes employing filtra-
tion for EV isolation and concen-
tration requires the use of sequential 
filtration steps or other purification 
methods and as such, are incapa-
ble of independently isolating EVs. 
Nevertheless, a recent study demon-
strated that ultrafiltration followed 
by liquid chromatography resulted 
in a significantly higher yield of EVs 
when compared with ultracentrifu-
gation, the current gold standard 
for EV purification [34]. The com-
bination of ultrafiltration and liquid 
chromatography represents a more 
capable process with respect to both 
scalability and isolation of EVs from 
more complex stem cell media [34]. 
Affinity-based selection allows 
for the isolation of EVs based on 
their surface protein profile. This 
can be achieved using magnetic or 
non-magnetic approaches that in-
corporate antibodies raised against 
proteins identified on the EV mem-
brane, such as the tetraspanin pro-
teins CD9, CD63 or CD81. How-
ever, since EVs are derived from the 
cell membrane there is considerable 
overlap in the surface protein pro-
files of each and, as yet, no specific 
marker has been identified to dis-
criminate EVs. Such methods are 
also typically low throughput and 
cannot be affordably scaled to pro-
duce a commercially and clinical 
viable product.
Storage
Despite growing interest in the 
study and application of EVs for 
diagnostic and therapeutic applica-
tions, little information is currently 
available concerning their storage. 
It has been suggested that different 
storage conditions may have a neg-
ative influence on the RNA con-
tained within EVs as well as the over-
all profile of these nano-particles. 
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Zhou and colleagues have previous-
ly shown that optimal recovery rates 
(86%) were best obtained for uri-
nary exosomes if stored at -80°C in 
the presence of protease inhibitors 
such as sodium azide, phenylmeth-
ane sulfonyl fluoride and leupeptin 
[35]. The exosomes remained intact 
and functional with no significant 
loss of associated protein markers, 
even when stored at -80°C for seven 
months. However, further research 
is required to validate these findings 
for EVs derived from stem cells. The 
fact that EVs appear to be stable at 
-80°C will also reduce costs associ-
ated with the specialized cryo-stor-
age of cell-based therapies.
Scalability 
Manufacturing high numbers of 
EVs from human primary stem cells 
is likely to prove a challenging task. 
This is primarily due to the fact 
that stem cell properties can vary 
if cell density, passage and culture 
conditions are not kept consistent. 
Stem cells lose their ‘stemness’ with 
increasing passage and it stands to 
reason that the therapeutic effects 
of EVs isolated from these cells will 
also be heavily constrained by the 
number of population doublings 
the parent cell has undergone. Po-
tency studies will be required to 
accurately define the window of 
passage within which stem cells 
generate therapeutically effective 
vesicles and if this can be enhanced 
through the incorporation of ag-
onists within the culture environ-
ment. If scaling of EVs for clinical 
and commercial purposes is to be 
satisfied, current large-scale man-
ufacturing methods for cell expan-
sion will need to be optimized and 
an optimal cell source identified. It 
may even prove necessary to geneti-
cally modify the cell source in order 
to maintain stem cell proliferation, 
and thereby allow production of 
EVs that is less restricted by passage. 
Since EVs are cell-derived products 
that contain no replicative material 
of their own, it is likely that changes 
can be made at a cellular level and 
are not necessarily propagated with-
in the EVs. 
Another significant challenge in 
the large-scale production of EVs 
is the inherent difficulties associat-
ed with their current manufacture 
and purification. Although a range 
of purification options are being 
considered (discussed above), the 
current production of EVs in-
volves large-scale cell culture in of-
ten complex media formulations, 
which can contain significant lev-
els of unwanted proteins and other 
complex macromolecular contami-
nants. This is particularly the case 
for processes that use fetal bovine 
serum (FBS) or human platelet ly-
sate (HPL). Whilst there is an in-
dustry-wide focus on using chem-
ically defined cell culture media, it 
is a significant scientific and tech-
nical challenge to adapt an existing 
FBS/HPL process to a serum-free 
one. 
A process for optimal EV produc-
tion from the cell source must also 
be defined, identifying appropriate 
medium compositions and reagents 
to facilitate both optimal EV yield 
and function. This includes under-
standing whether a batch, fed-batch 
or continuous process is more ap-
propriate for EV production with-
out impacting on cell proliferation. 
A range of different bioreactor plat-
forms as well as the operational pa-
rameters for such systems will need 
to be considered to achieve scaling 
demands whilst maintaining EV 
function. At present, hollow fiber 
and packed-bed bioreactors have 
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been used for the continuous pro-
duction of highly concentrated EVs 
at scale. Hollow fiber reactors that 
apply a fiber-base cartridge with a 
molecular weight cut-off are con-
sidered advantageous as this enables 
the diffusion of nutrients and waste 
products while retaining the thera-
peutically valuable EVs [36]. How-
ever, stirred-tank bioreactors are 
also likely to be considered as a key 
platform for manufacture given the 
legacy of using such systems for bio-
logics production [37] as well as the 
increasing propensity to use such 
platforms for adherent cell cultures 
in conjunction with microcarriers 
[38–40]. Stirred-tank bioreactors 
can be operated with spin filters to 
avoid the removal of cells/microcar-
riers during the process whilst fa-
cilitating the addition and removal 
of metabolites, growth factors and 
other secreted vesicles in a continu-
ous fashion. Moreover, stirred-tank 
bioreactors have proven scalability 
and a rich heritage for the produc-
tion of biologics, making adoption 
by biopharmaceutical companies 
which such platforms more likely. 
Scalability will also be determined 
by the nature of the cell source itself. 
Whilst there is a trend toward stem 
cell-derived EVs, most of which are 
adherent cells by nature, there are 
other non-adherent stem cells (e.g., 
hematopoietic) and immunological 
cell types that may be considered for 
EV production and are suspension 
by nature, or could be genetically 
engineered to proliferate in suspen-
sion cultures. As such, platforms that 
are specifically designed for adherent 
cells such as hollow-fibre bioreactors 
will not be considered and there will 
be a focus on employing existing 
platforms that are used to manufac-
ture suspension-based processes such 
as stirred-tank bioreactors. 
Characterization, safety & 
regulation
A common challenge across the cell 
and gene therapy field is the lack of 
effective and reproducible potency 
assays. This is similarly a significant 
barrier to effective translation for 
EVs, whereby the lack of both in vi-
tro and in vivo assays may hamper 
progress in the field. However, given 
the need for such assays, this is now 
a major focus across the industry 
and it is expected that significant de-
velopments will emerge as we devel-
op a better understanding about the 
biodistribution of cells and EVs and 
their mode of action. 
A number of safety and regulato-
ry requirements need to be satisfied 
before the pharmaceutical manu-
facturing and clinical application of 
EV-based therapies can be realized. 
Given the infancy of the R&D ac-
tivity for EV-based therapeutics, 
there are understandably no assays 
for safety testing, and limited in-
formation about localization and 
biodistribution profiles. There must 
also be consideration of the safety of 
the cell source from which the EVs 
are derived. However, given the 
similarities with biopharmaceutical 
production, significant learning can 
be applied from the sector. From a 
clinical perspective, aside from is-
sues described earlier relating to a 
lack of understanding of the MoA, 
both dose finding and toxicity stud-
ies need to be satisfied, and immune 
and tumorigenic response to EVs 
fully evaluated. From a regulatory 
perspective, it will be important to 
define whether EVs represent the 
active drug component or whether 
they primarily serve as the delivery 
vehicle for a drug. As such, signif-
icant improvements are required 
with respect to EV characteriza-
tion and standardization. This was 
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TRANSLATIONAL INSIGHT
There is a growing body of evidence 
demonstrating the potential of EVs 
for both clinical and diagnostics 
applications. However, as with the 
cell therapy field, it is important 
that significant emphasis is placed 
on understanding the fundamen-
tal MoA of EVs so as to begin 
addressing some of the characteriza-
tion, standardization and manufac-
turing challenges. This also involves 
understanding with respect to the 
scalable production of both the cell 
source as well as the fundamental 
bioprocessing conditions required 
to enable the reproducible produc-
tion and purification of therapeuti-
cally relevant EVs.
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